The study sought to provide an insight into the prevalence, characterization and possible reliable indicators of early sudden cardiac death/malignant ventricular arrhythmias (SCD/MVAs) in a large cohort of dilated cardiomyopathy (DCM). BACKGROUND DCM generally affects young individuals and is characterized by an unpredictable prognosis with a non-negligible risk of SCD/MVAs, particularly in early stages of disease. METHODS From 1988 to 2014, 952 patients with DCM were consecutively included in the Heart Muscle Disease Registry of Trieste. RESULTS Globally, 20 patients (2.1% of the overall population) experienced SCD/MVAs within the first 6 months after enrollment (primary endpoint). At baseline they showed a worse functional class (New York Heart Association functional class III to IV 42% vs. 22%, p 1⁄4 0.038), a longer QRS complex duration (127 ` 41 ms vs. 108 ` 33 ms; p 1⁄4 0.013) and a larger indexed left ventricular end-systolic volume (LVESVI) (82 ` 49 ml/m2 vs. 67 ` 34 ml/m2; p 1⁄4 0.049), as compared to patients without early SCD/MVAs. Beta-blockers were less tolerated (59% vs. 83% in patients with no early SCD/MVAs; p 1⁄4 0.008), mostly due to hemodynamic intolerance. At multivariate analysis, LVESVI (odds ratio [OR]: 1.012; 95% confidence interval [CI]: 1.000 to 1.024; p 1⁄4 0.043) and QRS complex duration (OR: 1.017; 95% CI: 1.003 to 1.030; p 1⁄4 0.015) were independently associated with the primary endpoint, whereas beta-blockers demonstrated a protective effect (OR: 0.169, CI: 0.048 to 0.593; p 1⁄4 0.006). CONCLUSIONS Patients with DCM present a significant risk of major arrhythmic events in the first phase of the disease. Baseline LVESVI, QRS duration, and intolerance to beta-blocker therapy might be useful tools in the arrhythmic early risk assessment

Early Arrhythmic Events in Idiopathic Dilated Cardiomyopathy

LOSURDO, Pasquale;STOLFO, DAVIDE;MERLO, MARCO;BARBATI, GIULIA;GOBBO, MARCO;GIGLI, MARTA;RAMANI, FEDERICA;PINAMONTI, BRUNO;ZECCHIN, MASSIMO;FINOCCHIARO, GHERARDO;MESTRONI, LUISA;SINAGRA, GIANFRANCO
2016

Abstract

The study sought to provide an insight into the prevalence, characterization and possible reliable indicators of early sudden cardiac death/malignant ventricular arrhythmias (SCD/MVAs) in a large cohort of dilated cardiomyopathy (DCM). BACKGROUND DCM generally affects young individuals and is characterized by an unpredictable prognosis with a non-negligible risk of SCD/MVAs, particularly in early stages of disease. METHODS From 1988 to 2014, 952 patients with DCM were consecutively included in the Heart Muscle Disease Registry of Trieste. RESULTS Globally, 20 patients (2.1% of the overall population) experienced SCD/MVAs within the first 6 months after enrollment (primary endpoint). At baseline they showed a worse functional class (New York Heart Association functional class III to IV 42% vs. 22%, p 1⁄4 0.038), a longer QRS complex duration (127 ` 41 ms vs. 108 ` 33 ms; p 1⁄4 0.013) and a larger indexed left ventricular end-systolic volume (LVESVI) (82 ` 49 ml/m2 vs. 67 ` 34 ml/m2; p 1⁄4 0.049), as compared to patients without early SCD/MVAs. Beta-blockers were less tolerated (59% vs. 83% in patients with no early SCD/MVAs; p 1⁄4 0.008), mostly due to hemodynamic intolerance. At multivariate analysis, LVESVI (odds ratio [OR]: 1.012; 95% confidence interval [CI]: 1.000 to 1.024; p 1⁄4 0.043) and QRS complex duration (OR: 1.017; 95% CI: 1.003 to 1.030; p 1⁄4 0.015) were independently associated with the primary endpoint, whereas beta-blockers demonstrated a protective effect (OR: 0.169, CI: 0.048 to 0.593; p 1⁄4 0.006). CONCLUSIONS Patients with DCM present a significant risk of major arrhythmic events in the first phase of the disease. Baseline LVESVI, QRS duration, and intolerance to beta-blocker therapy might be useful tools in the arrhythmic early risk assessment
http://www.sciencedirect.com/science/article/pii/S2405500X16301177
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S2405500X16301177-main.pdf

non disponibili

Tipologia: Documento in Versione Editoriale
Licenza: Digital Rights Management non definito
Dimensione 477.97 kB
Formato Adobe PDF
477.97 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11368/2896833
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 19
  • ???jsp.display-item.citation.isi??? ND
social impact